IMVT Immunovant Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMVT

Price (delayed)

$16.05

Market cap

$2.09B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$1.66B

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous ...

Highlights
Immunovant's debt has decreased by 45% YoY and by 16% QoQ
The equity has contracted by 18% YoY but it has grown by 4.8% from the previous quarter
IMVT's net income is down by 44% YoY and by 12% from the previous quarter
Immunovant's EPS has decreased by 28% YoY and by 8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://immunovant.com
Peers: OVID

Key stats

What are the main financial stats of IMVT
Market
Shares outstanding
130.25M
Market cap
$2.09B
Enterprise value
$1.66B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$197.71M
EBITDA
-$196.41M
Free cash flow
-$165.65M
Per share
EPS
-$1.66
Free cash flow per share
-$1.29
Book value per share
$3.21
Revenue per share
$0
TBVPS
$3.55
Balance sheet
Total assets
$456.24M
Total liabilities
$41.57M
Debt
$1.51M
Equity
$414.68M
Working capital
$413.16M
Liquidity
Debt to equity
0
Current ratio
11.01
Quick ratio
10.5
Net debt/EBITDA
2.19
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-42.8%
Return on equity
-46.3%
Return on invested capital
N/A
Return on capital employed
-47.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMVT stock price

How has the Immunovant stock price performed over time
Intraday
-0.99%
1 week
4.15%
1 month
-11.13%
1 year
166.61%
YTD
-9.58%
QTD
-9.58%

Financial performance

How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$202.18M
Net income
-$198.7M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 47% year-on-year and by 14% since the previous quarter
IMVT's net income is down by 44% YoY and by 12% from the previous quarter

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation
P/E
N/A
P/B
5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 28% YoY and by 8% QoQ
The stock's price to book (P/B) is 110% more than its last 4 quarters average of 2.4
The equity has contracted by 18% YoY but it has grown by 4.8% from the previous quarter

Efficiency

How efficient is Immunovant business performance
IMVT's return on equity has dropped by 51% year-on-year and by 18% since the previous quarter
IMVT's return on assets is down by 49% year-on-year and by 18% since the previous quarter

Dividends

What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time
IMVT's total liabilities is up by 28% since the previous quarter and by 9% year-on-year
IMVT's quick ratio is down by 28% year-on-year and by 19% since the previous quarter
Immunovant's debt is 100% lower than its equity
The debt to equity has dropped by 100% year-on-year
Immunovant's debt has decreased by 45% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.